Metagenomi Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Metagenomi Therapeutics, Inc. (MGX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are MGX insiders buying or selling?
In the last 12 months, Metagenomi Therapeutics, Inc. insiders reported 1 open-market purchase ($23.4K) and 17 sales ($44.1K) — net selling of $20.7K. Since February 2024, Trabud has recorded 28 Form 4 filings for MGX: 2 buys ($13.0M) and 26 sells ($112.5K).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $23.4K by Laurence Reid (Director) on Sep 11, 2026. SEC ↗
- The most recent open-market purchase was reported on Sep 11, 2026 (37 days ago).
Key Statistics (February 2024 – Sep 11, 2026)
Total Form 4 filings
28
SEC EDGAR
Insider filers
7
Insider buys (2)
$13.0M
Insider sells (26)
$112.5K
Insider sentiment
Net buyingNet insider flow of $12.9M in net buying since February 2024, and $20.7K in net selling over the last 12 months. 1 insider buy in the last 90 days.
Recent MGX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Laurence Reid | Director | Purchase | 20.0K | $1.17 | $23.4K | SEC ↗ |
| Sep 10, 2026 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 358 | $1.16 | $414.71 | SEC ↗ |
| Sep 10, 2026 | Jian Irish | President and Chief Executive Officer | Sale | 2.1K | $1.16 | $2.5K | SEC ↗ |
| Sep 10, 2026 | Pamela Wapnick | Chief Financial Officer | Sale | 1.9K | $1.16 | $2.2K | SEC ↗ |
| Jun 10, 2026 | Pamela Wapnick | Chief Financial Officer | Sale | 2.9K | $1.30 | $3.7K | SEC ↗ |
| Jun 10, 2026 | Jian Irish | President and Chief Executive Officer | Sale | 3.7K | $1.30 | $4.9K | SEC ↗ |
| Jun 10, 2026 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 558 | $1.30 | $724.84 | SEC ↗ |
| Mar 9, 2026 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.60 | $2.5K | SEC ↗ |
| Mar 9, 2026 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 482 | $1.60 | $771.2 | SEC ↗ |
| Mar 9, 2026 | Jian Irish | Chief Executive Officer | Sale | 1.6K | $1.60 | $2.6K | SEC ↗ |
| Dec 8, 2025 | Brian C. Thomas | Director | Sale | 3.8K | $1.77 | $6.8K | SEC ↗ |
| Dec 8, 2025 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 199 | $1.77 | $352.61 | SEC ↗ |
| Dec 8, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.77 | $2.8K | SEC ↗ |
| Dec 8, 2025 | Jian Irish | Chief Executive Officer | Sale | 1.6K | $1.77 | $2.8K | SEC ↗ |
| Dec 2, 2025 | Brian C. Thomas | Director | Sale | 2.7K | $1.81 | $4.9K | SEC ↗ |
| Dec 2, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.81 | $2.9K | SEC ↗ |
| Dec 2, 2025 | Jian Irish | Chief Executive Officer | Sale | 1.6K | $1.81 | $2.9K | SEC ↗ |
| Dec 1, 2025 | Matthew Wein | Title: General Counsel, Compliance Officer and Corporate Secretary | Sale | 199 | $1.81 | $360.19 | SEC ↗ |
| Jun 9, 2025 | Matthew Wein | Title: Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary | Sale | 199 | $1.75 | $348.25 | SEC ↗ |
| Jun 9, 2025 | Sarah B. Noonberg | Chief Medical Officer | Sale | 5.2K | $1.75 | $9.2K | SEC ↗ |
| Jun 9, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.6K | $1.75 | $2.8K | SEC ↗ |
| Jun 9, 2025 | Brian C. Thomas | Chief Executive Officer | Sale | 10.8K | $1.75 | $18.9K | SEC ↗ |
| Jun 9, 2025 | Jian Irish | Title: President and Chief Operating Officer | Sale | 6.4K | $1.75 | $11.2K | SEC ↗ |
| Mar 7, 2025 | Matthew Wein | Title: Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary | Sale | 930 | $1.87 | $1.7K | SEC ↗ |
| Mar 7, 2025 | Pamela Wapnick | Chief Financial Officer | Sale | 1.8K | $1.87 | $3.4K | SEC ↗ |
Showing the 25 most recent of 28 Form 4 filings for Metagenomi Therapeutics, Inc..
Most active MGX insiders
- Pamela Wapnick9 filings
- Matthew Wein7 filings
- Jian Irish6 filings
- Brian C. Thomas3 filings
- Laurence Reid1 filing
Ask anything about MGX insider activity
Use Trabud's AI agent to query Metagenomi Therapeutics, Inc.'s Form 4 history in plain English — "Show me MGX CEO purchases this year" or compare it against any other ticker.
Open the AI agentMGX insider trading FAQ
Are Metagenomi Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Metagenomi Therapeutics, Inc. insiders reported 1 open-market purchase ($23.4K) and 17 sales ($44.1K) — net selling of $20.7K. Since February 2024, Trabud has recorded 28 Form 4 filings for MGX: 2 buys ($13.0M) and 26 sells ($112.5K). Over the full record that is net buying of $12.9M.
How many insiders trade MGX stock?
7 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Metagenomi Therapeutics, Inc.. The most recent filing was accepted on Sep 11, 2026.
Where does Trabud get MGX insider trading data?
All MGX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.